BBR 2550

Drug Profile

BBR 2550

Alternative Names: BBR-2550; Na[trans RuCl4(DMSO)Im] . 2DMSO; NSC 637823-T/1

Latest Information Update: 15 Mar 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer metastases

Most Recent Events

  • 15 Mar 2007 Discontinued - Preclinical for Cancer metastases in Italy (unspecified route)
  • 21 Sep 1999 No-Development-Reported for Cancer metastases in Italy (Unknown route)
  • 21 Mar 1997 Preclinical development for Cancer metastases in Italy (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top